netFormulary NHS
Birmingham, Sandwell, Solihull and environs APC Formulary
Maintained by Midlands and Lancashire Commissioning Support Unit
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund list

 Details...
08.01.03  Expand sub section  Antimetabolites
Cytotoxic Drug Azacitidine (Vidaza®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA218: azacitidine for myelodysplastic syndromes
   
Cytotoxic Drug Capecitabine (Tablets)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Link  NICE TA191: Gastric cancer (advanced) - capecitabine
Link  NICE TA61: Colorectal cancer - capecitabine and tegafur uracil
   
Cytarabine–daunorubicin liposomal (Vyxeos®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

In line with NICE

 
Link  NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
   
Cytotoxic Drug Fludarabine Phosphate
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA119: Leukaemia (lymphocytic) - fludarabine
Link  NICE TA29: Leukaemia (lymphocytic) - fludarabine
   
Cytotoxic Drug Gemcitabine (Gemzar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE NG85: Pancreatic cancer in adults: diagnosis and management
Link  NICE TA116: Breast cancer - gemcitabine
   
Cytotoxic Drug Mercaptopurine (Tablets)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
   
Cytotoxic Drug Methotrexate 2.5mg (Tablets)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  UKMI Q&A: Should patients drink alcohol whilst taking long-term low-dose methotrexate?
Link  UKMI Q&A: What is the clinical significance of the interaction between methotrexate and penicillins? (Oct13)
   
Cytotoxic Drug Pemetrexed (Alimta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
 
Link  NICE TA124: Lung cancer (non-small-cell) - pemetrexed - prior chemotherapy
Link  NICE TA135: Mesothelioma - pemetrexed disodium
Link  NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Link  NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Link  NICE TA402: Lung cancer (non-squamous non-small-cell) after pemetrexed and cisplatin: Pemetrexed (maintenance)
   
Raltitrexed (Tomudex®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE CG131:Colorectal cancer: diagnosis and management
   
Cytotoxic Drug Tioguanine (Tablets)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
   
Cytotoxic Drug Trifluridine-tipiracil  (Lonsurf ®)
(Tablets)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • In line with NICE
  • Hospital only- NHSE commissioned 
  • Link  NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
       
     ....
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Prescribing in children

    The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.

    The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.

      

    Green

    Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications.  

    Amber

    Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.

    Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements.   

    Red

    Medicines for initiation and maintenance prescribing by Specialists only  

    Black

    Non-formulary medicines- medicines not recommended for routine primary care prescribing.  

    Grey

    Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information.  

    netFormulary